Table 1.
Patient characteristics.
| Characteristic | Discovery Cohort (n = 12) |
Validation Cohort 1 (n = 60) | Validation Cohort 2 (n = 60) | p | Total Cohort (n = 132) |
|---|---|---|---|---|---|
| Age (years), median (range) |
64 (49–78) | 66 (41–81) | 62 (49–79) | 0.601 | 64 (41–81) |
| Sex, male (%) | 7 (58.3) | 34 (56.7) | 36 (60.0) | 0.934 | 77 (58.3) |
| Stage of disease (%) (Borderline) resectable Locally advanced Metastatic |
2 (16.7) 4 (33.3) 6 (50.0) |
29 (48.3) 18 (30.0) 13 (21.7) |
31 (51.7) 23 (38.3) 6 (10.0) |
0.016 |
62 (47.0) 45 (34.1) 25 (18.9) |
| Cycles of FOLFIRINOX received, median (range) |
4 (2–12) | 8 (2–12) | 8 (1–12) | 0.087 | 8 (1–12) |
| Baseline CA19-9 (kU/L), median (IQR) |
410 (74.5–9341.0) | 147.5 (51.8–910.3) | 216.0 (51.0–845.0) | 0.315 | 190.0 (51.0–1050.0) |
| RECIST response outcome after FOLFIRINOX a (%) Disease control Progressive disease |
6 (50.0) 6 (50.0) |
46 (76.7) 14 (23.3) |
47 (78.3) 13 (21.7) |
0.108 |
99 (75.0) 33 (25.0) |
a According to the RECIST 1.1 criteria. CA19-9 = carbohydrate antigen 19-9, IQR = interquartile range. p-values are calculated by Kruskal–Wallis tests (continuous data) or Chi-squared tests (categorical data).